137 related articles for article (PubMed ID: 8061280)
21. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat.
Orosz D; Bennett JP
Exp Neurol; 1992 Mar; 115(3):388-93. PubMed ID: 1537396
[TBL] [Abstract][Full Text] [Related]
22. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
23. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Vandeneede D; Ebinger G; Michotte Y
J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
[TBL] [Abstract][Full Text] [Related]
24. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Wachtel SR; Abercrombie ED
J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
26. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
Xu D; Karain B; Brantley E; Shi WX
J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
[TBL] [Abstract][Full Text] [Related]
27. Dual effects of L-DOPA on nigral dopaminergic neurons.
Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
[TBL] [Abstract][Full Text] [Related]
28. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Kannari K; Tanaka H; Maeda T; Tomiyama M; Suda T; Matsunaga M
J Neurochem; 2000 Jan; 74(1):263-9. PubMed ID: 10617128
[TBL] [Abstract][Full Text] [Related]
29. Chronic L-DOPA-pretreatment of rats: an electrophysiological and biochemical study in the basal ganglia.
Jackson DM; Walters JR; Miller LP
Brain Res; 1982 Nov; 250(2):271-82. PubMed ID: 6129029
[TBL] [Abstract][Full Text] [Related]
30. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
31. Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation.
Mohanakumar KP; de Bartolomeis A; Wu RM; Yeh KJ; Sternberger LM; Peng SY; Murphy DL; Chiueh CC
Ann N Y Acad Sci; 1994 Nov; 738():392-9. PubMed ID: 7832447
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of dopamine metabolism by in vivo voltammetry and high performance liquid chromatography in L-dopa-treated rats.
Aoki S; Inukai K; Sakurai M; Koshikawa N; Kobayashi M
Jpn J Pharmacol; 1987 Jan; 43(1):98-102. PubMed ID: 3573420
[TBL] [Abstract][Full Text] [Related]
33. Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors.
Alexander T; Sortwell CE; Sladek CD; Roth RH; Steece-Collier K
Cell Transplant; 1997; 6(3):309-15. PubMed ID: 9171163
[TBL] [Abstract][Full Text] [Related]
34. An investigation of dopaminergic metabolites in the striatum and in the substantia nigra in vivo utilising radiolabelled L-DOPA and high performance liquid chromatography: a new approach in the search for transmitter metabolites.
Niazi Shahabi H; Bergquist F; Nissbrandt H
Neuroscience; 2003; 120(2):425-33. PubMed ID: 12890512
[TBL] [Abstract][Full Text] [Related]
35. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
[TBL] [Abstract][Full Text] [Related]
36. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
37. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
38. A microdialysis study on striatal dopamine, 5-HT and metabolites in conscious rats after various treatments: evidence for extravesicular release of dopamine.
Wong PT; Teo WL; Lee T
Neuroreport; 1993 Oct; 5(1):53-6. PubMed ID: 7506588
[TBL] [Abstract][Full Text] [Related]
39. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
40. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
